Slide 1: Financial Results
Financial Results Full Year and Quarter Ended March 31, 2018
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : May, 09, 2018 Time : 05:00 pm IST Primary Number: + 91 22 7115 8042 +91‐7045671221 Local Access Number: Available all over India. USA: 1 866 746 2133 UK: 0 808 101 1573 Toll Free Number: Singapore: 800 101 2045 Hong Kong: 800 964 448 Replay from : May 09 to 15, 2018 Di
Slide 4: Q4'FY18 and FY18 Results Analysis
Q4’FY18 and FY18 Results Analysis 33
Slide 5: Income Statement – Q4'FY18
Income Statement – Q4’FY18 Particulars Q4'FY17 Q3'FY18 Q4'FY18 YoY Growth QoQ Growth (Rs Crs) (%) Total Revenue from Operations (Net of Excise) 1,598 2,068 2,252 41% 9% Pharmaceuticals 804 1,101 1,238 54% 12% Life Science Ingredients 743 922 968 30% 5% Drug Discovery Solutions 51 45 47 ‐8% 5% Total
Slide 6: Financial Highlights – Q4'FY18
Financial Highlights – Q4’FY18 • Consolidated revenue at Rs. 2,252 Crore, up 41% YoY and 9% QoQ • Pharmaceuticals revenue at Rs. 1,238 Crore, contributing 55% to revenue, up 54% YoY and 12% QoQ • Life Science Ingredients revenue at Rs. 968 Crore, contributing 43% to revenue, up 30% YoY and 5% QoQ •
Slide 7: Income Statement – FY18
Income Statement – FY18 Particulars FY17 FY18 YoY Growth (Rs Crs) (%) Total Revenue from Operations (Net of Excise) 5,861 7,518 28% Pharmaceuticals 3,104 4,013 29% Life Science Ingredients 2,576 3,328 29% Drug Discovery Solutions 182 176 ‐3% Total Expenditure 4,516 5,999 33% Other Income 25 40 61% E
Slide 8: Financial Highlights – FY18
Financial Highlights – FY18 • Consolidated revenue at Rs. 7,518 Crore, up 28% YoY • Pharmaceuticals revenue at Rs. 4,013 Crore, up 29% YoY, contributing 53% to the revenues • LSI revenue at Rs. 3,328 Crore, up 29% YoY, contributing 44% to the revenues • Drug Discovery Solutions revenue at Rs. 176 Cr
Slide 9: Segmental Revenue Analysis – FY18
Segmental Revenue Analysis – FY18 Revenue Segmental Revenue Analysis (Rs. Crs.) Revenue YoY • Company reports highest‐ever Mix (%) Growth % revenue of Rs. 7,518 Crore, driven FY17 FY18 by improvement in Pharmaceuticals 3,104 4,013 53% 29% Pharmaceuticals and Life Science Generics 1,448 1,375 18% ‐5%
Slide 10: Pharmaceuticals Segment Highlights
Pharmaceuticals Segment Highlights Geo‐wise Revenue (Rs crs) Q4'FY17 Q3'FY18 Q4'FY18 Mix % YoY % QoQ % International 767 1,067 1,203 97% 57% 13% North America 580 915 992 80% 71% 8% Europe & Japan 130 85 129 10% ‐1% 51% ROW 57 66 82 7% 44% 24% India 37 34 35 3% ‐6% 3% Income from Operations 804 1,10
Slide 11: Pharmaceuticals Segment Highlights
Pharmaceuticals Segment Highlights • Pharmaceuticals revenue at Rs. 4,013 Crore, up 29% YoY, contributing 53% to the revenues • Specialty Injectables reported revenues of Rs. 2,639 Crore, showing robust growth of 59% YoY, contributing 66% to Pharma segment sales as compared to 53% in FY17 • Revenues
Slide 12: Regulatory Status
Regulatory Status Regulatory Cadista Roorkee CMO / Allergy CMO JDI Montreal Nanjangud • All sites successfully Agency USA India Spokane Montreal Canada India inspected and fully compliant with USFDA Mar 2017 Mar 2017 Sep 2017 Dec 2016 Sep 2017 Oct 2017 (USA) regulations Oct 2017 Apr 2016 Oct 2017 •
Slide 13: Portfolio of R&D products – Filings and Approvals
Portfolio of R&D products – Filings and Approvals Product pipeline as on March 31, 2018 Dosage (Orals) Steriles Region Total Filings Approval Pending Total Filings Approval Pending US 94 59 35 12 10 2 Canada 22 22 ‐ 13 13 ‐ Europe 103 95 8 10 10 ‐ ROW 710 504 206 44 40 4 Total 929 680 249 79 73 6 We
Slide 14: Portfolio of R&D products – Filings and Approvals
Portfolio of R&D products – Filings and Approvals Dosage (Orals) Filed 94 ANDAs in the US i. 59 ANDAs have been approved and 35 ANDAs are pending approval ii. Filed 10 ANDAs in FY18 (in‐house) + 1 Inlicensed product Made 835 filings in ROW (ex‐US) markets including Canada, Europe and Japan i. 62
Slide 15: LSI Segment Highlights
LSI Segment Highlights Geo‐wise Revenue (Rs crs) Q4'FY17 Q3'FY18 Q4'FY18 Mix % YoY % QoQ % International 335 371 374 39% 12% 1% Europe, North America and Japan 227 243 250 26% 10% 3% ROW 108 128 124 13% 15% ‐3% India 408 551 593 61% 45% 8% Income from Operations 743 922 968 100% 30% 5% Geo‐wise Reve
Slide 16: LSI Segment Highlights
LSI Segment Highlights FY18 revenue at Rs. 3,328 Crore, up 29% YoY, contributing 44% to the revenues Specialty Intermediates: • Revenues at Rs. 970 Crore, up 7% YoY • Launched 7 products during the year and 6 more to be launched in FY19 • Commissioned cGMP Plant in Bharuch for supplies to pharma and
Slide 17: Drug Discovery Solutions Segment Highlights
Drug Discovery Solutions Segment Highlights Revenue at Rs. 176 Crore during FY18 • Pipeline of Integrated Drug Discovery Projects, functional projects & FTE business continues to be strong • Increased effort & focus on in‐house proprietary research for out‐licensing molecules or onboarding new proje
Slide 18: Expenditure Analysis – Q4'FY18
Expenditure Analysis – Q4’FY18 % of % of % of YoY QoQ Expenses (Rs Crs) Q4'FY17 Q3'FY18 Q4'FY18 Sales Sales Sales Growth % Growth % Material Cost and Change in Inventory 548 34% 707 34% 817 36% 49% 16% Purchases of stock‐in‐trade 42 3% 79 4% 73 3% 73% ‐8% Employee benefits expense 324 20% 423 20% 45
Slide 19: Expenditure Analysis – FY18
Expenditure Analysis – FY18 Expenses (Rs Crs) FY17 % of Sales FY18 % of Sales YoY Growth % Material Cost and Change in Inventory 1,814 31% 2,626 35% 45% Purchases of stock‐in‐trade 185 3% 243 3% 31% Employee benefits expense 1,231 21% 1,556 21% 26% Power and fuel expense 334 6% 425 6% 27% Others 952
Slide 20: Debt Profile
Debt Profile Particulars 31‐Mar‐17 31‐Dec‐17 31‐Mar‐18 Foreign Currency Loans ($ Mn) ($ Mn) ($ Mn) Standalone 19 0 9 Subsidiaries (incl. Stock Settlement Instrument) 407 374 358 Total 426 374 367 Rupee Loans (Rs. Crs) (Rs. Crs) (Rs. Crs) Standalone 1,241 1,227 1,007 Subsidiaries 82 101 79 Total 1,32
Slide 21: Outlook
Outlook We see a clear roadmap for growth in our businesses both in revenues and profitability in FY19, with H2’FY19 expected to be better than H1’FY19. The growth drivers for each of the business are as follows: • Specialty Injectables: • Growth from new products and execution of existing contrac
Slide 22: For more information
For more information For Investors: Ravi Agrawal Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91 120 436 1002 Ph: +91 22 6645 1209 E‐mail: ravi.agrawal@jubl.com E‐mail: siddharth@cdr‐india.com For Media: Sudhakar Safaya Sulakshana Mehrotra Jubilant Life Sciences Limited Perfect